147 related articles for article (PubMed ID: 16527213)
21. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
22. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
23. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
Srinivasan R; Maxwell SA
Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
[TBL] [Abstract][Full Text] [Related]
24. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
Gurova KV; Rokhlin OW; Budanov AV; Burdelya LG; Chumakov PM; Cohen MB; Gudkov AV
Cancer Res; 2003 Jun; 63(11):2905-12. PubMed ID: 12782597
[TBL] [Abstract][Full Text] [Related]
25. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
Tarunina M; Jenkins JR
Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
27. In vitro structure-function analysis of the beta-strand 326-333 of human p53.
Chène P; Mittl P; Grütter M
J Mol Biol; 1997 Nov; 273(4):873-81. PubMed ID: 9367778
[TBL] [Abstract][Full Text] [Related]
28. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
29. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
[TBL] [Abstract][Full Text] [Related]
30. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis.
Chang F; Syrjänen S; Kurvinen K; Syrjänen K
Am J Gastroenterol; 1993 Feb; 88(2):174-86. PubMed ID: 8424417
[TBL] [Abstract][Full Text] [Related]
31. Distinct regions of p53 have a differential role in transcriptional activation and repression functions.
Sang BC; Chen JY; Minna J; Barbosa MS
Oncogene; 1994 Mar; 9(3):853-9. PubMed ID: 8108128
[TBL] [Abstract][Full Text] [Related]
32. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
Nagata Y; Anan T; Yoshida T; Mizukami T; Taya Y; Fujiwara T; Kato H; Saya H; Nakao M
Oncogene; 1999 Oct; 18(44):6037-49. PubMed ID: 10557093
[TBL] [Abstract][Full Text] [Related]
33. Specific binding of MAR/SAR DNA-elements by mutant p53.
Müller BF; Paulsen D; Deppert W
Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
[TBL] [Abstract][Full Text] [Related]
34. [P53 and cancers].
May P; May E
Pathol Biol (Paris); 1995 Mar; 43(3):165-73. PubMed ID: 7675543
[TBL] [Abstract][Full Text] [Related]
35. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
36. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
[TBL] [Abstract][Full Text] [Related]
37. [Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants].
Almazov VP; Morgunkova AA; Kalinin VN; Kopnin BP; Prasolov VS; Chumakov PM
Mol Biol (Mosk); 2002; 36(4):664-71. PubMed ID: 12173471
[TBL] [Abstract][Full Text] [Related]
38. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
39. p53 DNA binding can be modulated by factors that alter the conformational equilibrium.
McLure KG; Lee PW
EMBO J; 1999 Feb; 18(3):763-70. PubMed ID: 9927436
[TBL] [Abstract][Full Text] [Related]
40. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
